However, several studies showed that FLT3-ITD+ mutation is a strong adverse prognostic factor in AML patients (Stirewalt et al., 2008; Kiyoi and Naoe 2006; Zheng and Small 2005) with reduced DFS and OS and increased RR (Kottaridis et al., 2001; Yanada et al., 2005; Canaani et al., 2018). The gene discussed is FLT3; the disease is acute myeloid leukemia.